Fosamprenavir

Declining Morbidity and Mortality among Patients with Advanced Human Immunodeficiency Virus Infection

1998 • 9,382 citations

A Controlled Trial of Two Nucleoside Analogues plus Indinavir in Persons with Human Immunodeficiency Virus Infection and CD4 Cell Counts of 200 per Cubic Millimeter or Less

1997 • 2,670 citations

The role of intestinal P-glycoprotein in the interaction of digoxin and rifampin

1999 • 911 citations

Modulators and substrates of P-glycoprotein and cytochrome P4503A coordinately up-regulate these proteins in human colon carcinoma cells.

1996 • 487 citations

The Pregnane X Receptor: A Promiscuous Xenobiotic Receptor That Has Diverged during Evolution

2000 • 487 citations

CYP3A4 Induction by Drugs: Correlation between a Pregnane X Receptor Reporter Gene Assay and CYP3A4 Expression in Human Hepatocytes

2002 • 438 citations

Esomeprazole provides improved acid control vs. omeprazole in patients with symptoms of gastro‐oesophageal reflux disease

2000 • 291 citations

The Pregnane X Receptor: A Promiscuous Xenobiotic Receptor That Has Diverged during Evolution

2000 • 260 citations

Inhibition of cytochrome P-450 3A (CYP3A) in human intestinal and liver microsomes: comparison of Ki values and impact of CYP3A5 expression.

1999 • 236 citations

HIV Protease Inhibitors Are Inhibitors but Not Substrates of the Human Breast Cancer Resistance Protein (BCRP/ABCG2)

2004 • 218 citations

Role of P-glycoprotein on the CNS disposition of amprenavir (141W94), an HIV protease inhibitor.

1999 • 216 citations

SOLO

2004 • 199 citations

Pharmacokinetics of Adjusted-Dose Lopinavir-Ritonavir Combined with Rifampin in Healthy Volunteers

2004 • 185 citations

Use of the nuclear receptor PXR to predict drug interactions

2000 • 183 citations

Cyp3A regulation: from pharmacology to nuclear receptors.

2001 • 163 citations

The NEAT Study: A 48-Week Open-Label Study to Compare the Antiviral Efficacy and Safety of GW433908 Versus Nelfinavir in Antiretroviral Therapy???Naive HIV-1-Infected Patients

2003 • 155 citations

Pharmacokinetic-Pharmacodynamic Analysis of Lopinavir-Ritonavir in Combination with Efavirenz and Two Nucleoside Reverse Transcriptase Inhibitors in Extensively Pretreated Human Immunodeficiency Virus-Infected Patients

2002 • 148 citations

Ritonavir induces P-glycoprotein expression, multidrug resistance-associated protein (MRP1) expression, and drug transporter-mediated activity in a human intestinal cell line

2001 • 130 citations

Induction of P-glycoprotein and cytochrome P450 3A by HIV protease inhibitors.

2001 • 128 citations

Assessment of active transport of HIV protease inhibitors in various cell lines and the in vitro blood–brain barrier

2001 • 120 citations

Genotypic Inhibitory Quotient as Predictor of Virological Response to Ritonavir-Amprenavir in Human Immunodeficiency Virus Type 1 Protease Inhibitor-Experienced Patients

2003 • 99 citations

Pharmacokinetic and Pharmacodynamic Study of the Human Immunodeficiency Virus Protease Inhibitor Amprenavir after Multiple Oral Dosing

2001 • 97 citations

Preclinical Pharmacology and Pharmacokinetics of GW433908, a Water-Soluble Prodrug of the Human Immunodeficiency Virus Protease Inhibitor Amprenavir

2004 • 95 citations

The effect of multiple doses of ritonavir on the pharmacokinetics of rifabutin*

1998 • 83 citations

The protease inhibitor ritonavir inhibits the functional activity of the multidrug resistance related-protein 1 (MRP-1)

2002 • 80 citations

Single-Dose Pharmacokinetics of Amprenavir, a Human Immunodeficiency Virus Type 1 Protease Inhibitor, in Subjects with Normal or Impaired Hepatic Function

2000 • 78 citations

Combination Therapy with Amprenavir, Abacavir, and Efavirenz in Human Immunodeficiency Virus (HIV)-Infected Patients Failing a Protease-Inhibitor Regimen: Pharmacokinetic Drug Interactions and Antiviral Activity

2000 • 76 citations

Pharmacokinetic Interaction between Amprenavir and Rifabutin or Rifampin in Healthy Males

2001 • 72 citations

The comparative effects of lansoprazole, omeprazole, and ranitidine in suppressing gastric acid secretion

1997 • 72 citations

Pharmacokinetic interaction between ritonavir and clarithromycin*

1998 • 71 citations

Effects of rabeprazole, 20 mg, or esomeprazole, 20 mg, on 24‐h intragastric pH and serum gastrin in healthy subjects

2002 • 68 citations

Lopinavir: acute exposure inhibits P-glycoprotein; extended exposure induces P-glycoprotein.

2003 • 61 citations

Interactions between amprenavir and the lopinavir-ritonavir combination in heavily pretreated patients infected with human immunodeficiency virus*1, *2

2004 • 59 citations

Ritonavir Decreases the Nonrenal Clearance of Digoxin in Healthy Volunteers with Known MDR1 Genotypes

2004 • 59 citations

Combining fosamprenavir with lopinavir/ritonavir substantially reduces amprenavir and lopinavir exposure: ACTG protocol A5143 results

2005 • 57 citations

Lopinavir

2003 • 56 citations

Maternal-fetal transfer and amniotic fluid accumulation of protease inhibitors in pregnant women who are infected with human immunodeficiency virus

2004 • 53 citations

Pharmacokinetic Interaction between Amprenavir and Clarithromycin in Healthy Male Volunteers

2000 • 48 citations

Six-Week Randomized Controlled Trial To Compare the Tolerabilities, Pharmacokinetics, and Antiviral Activities of GW433908 and Amprenavir in Human Immunodeficiency Virus Type 1-Infected Patients

2003 • 46 citations

Lack of Enzyme‐Inducing Effect of Rifampicin on the Pharmacokinetics of Enfuvirtide

2003 • 45 citations

Pharmacokinetic Interaction between Ketoconazole and Amprenavir after Single Doses in Healthy Men

1999 • 42 citations

The Pharmacokinetics of Amprenavir, Zidovudine, and Lamivudine in the Genital Tracts of Men Infected with Human Immunodeficiency Virus Type 1 (AIDS Clinical Trials Group Study 850)

2002 • 40 citations

Effect of Antacids and Ranitidine on the Single-Dose Pharmacokinetics of Fosamprenavir

2004 • 39 citations

Deep Salvage With Amprenavir and Lopinavir/Ritonavir

2004 • 37 citations

TheEx Vivo human placental transfer of the anti-HIV nucleoside inhibitor abacavir and the protease inhibitor amprenavir

1998 • 35 citations

Pharmacokinetics and Pharmacodynamics of Methadone Enantiomers After Coadministration with Amprenavir in Opioid‐Dependent Subjects

2004 • 35 citations

Pharmacokinetics and safety of GW433908 and ritonavir, with and without efavirenz, in healthy volunteers

2004 • 34 citations

Statistical Issues in a Modeling Approach to Assessing Bioequivalence or PK Similarity with Presence of Sparsely Sampled Subjects

2004 • 34 citations

Steady-State Pharmacokinetics of Saquinavir Hard-Gel/Ritonavir/Fosamprenavir in HIV-1???Infected Patients

2004 • 34 citations

Pharmacokinetic interaction between amprenavir and delavirdine: Evidence of induced clearance by amprenavir

2002 • 26 citations

Pharmacodynamics and kinetics of omeprazole MUPS 20 mg and pantoprazole 40 mg during repeated oral administration in Helicobacter pylori‐negative subjects

2000 • 26 citations

Lack of Interaction between Enfuvirtide and Ritonavir or Ritonavir‐Boosted Saquinavir in HIV‐1‐Infected Patients

2004 • 25 citations

Salvage Therapy with Amprenavir, Lopinavir and Ritonavir 200 Mg/D or 400 Mg/D in HIV-Infected Patients in Virological Failure

2004 • 24 citations

Pharmacokinetic Study of Human Immunodeficiency Virus Protease Inhibitors Used in Combination with Amprenavir

2001 • 23 citations

Metabolic Disposition and Pharmacokinetics of [¹⁴C]‐Amprenavir, a Human Immunodeficiency Virus Type 1 (HIV‐1) Protease Inhibitor, Administered As a Single Oral Dose to Healthy Male Subjects

2001 • 21 citations

Pharmacokinetic interaction between amprenavir and delavirdine after multiple‐dose administration in healthy volunteers

2003 • 17 citations

Ritonavir Increases Plasma Amprenavir (APV) Exposure to a Similar Extent when Coadministered with either Fosamprenavir or APV

2006 • 13 citations

Pharmacokinetics of Indinavir and Ritonavir Administered at 667 and 100 Milligrams, Respectively, Every 12 Hours Compared with Indinavir Administered at 800 Milligrams Every 8 Hours in Human Immunodeficiency Virus-Infected Patients

2004 • 13 citations

Effects of Formulation and Dosing Strategy on Amprenavir Concentrations in the Seminal Plasma of Human Immunodeficiency Virus Type 1–Infected Men

2002 • 13 citations

A randomized study investigating the efficacy and safety of amprenavir in combination with low‐dose ritonavir in protease inhibitor‐experienced HIV‐infected adults

2004 • 11 citations

Thermosensory threshold: a sensitive test of HIV associated peripheral neuropathy?

1998 • 10 citations

Effervescent and standard formulations of ranitidine—a comparison of their pharmacokinetics and pharmacology

1996 • 10 citations